Collegium Pharmaceutical (COLL) Set to Post Quarterly Earnings on Thursday

Key Points

• Collegium Pharmaceutical is expected to report Q3 2026 results before market open on Thursday, November 5, with analysts forecasting $1.86 in earnings per share and $216.03 million in revenue.
• The company’s latest quarter exceeded expectations, with EPS of $1.92 versus the $1.72 consensus and revenue of $199.88 million, up 6.3% year over year.
• COLL shares recently traded near $23.23, well below their 52-week high of $50.79, while analysts maintain a “Moderate Buy” consensus and an average price target of $48.71.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) will likely be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Collegium Pharmaceutical to post earnings of $1.86 per share and revenue of $216.03 million for the quarter. Individuals may review the information on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, beating analysts' consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The company had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. During the same period last year, the firm earned $1.68 earnings per share. The firm's revenue was up 6.3% on a year-over-year basis. On average, analysts expect Collegium Pharmaceutical to post $6.42 EPS for the current fiscal year and $5.89 EPS for the next fiscal year.

Collegium Pharmaceutical Stock Up 1.0%

COLL stock opened at $23.23 on Thursday. The stock has a market cap of $756.37 million, a P/E ratio of 18.73, a P/E/G ratio of 0.71 and a beta of 0.73. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. The stock's fifty day simple moving average is $23.47 and its two-hundred day simple moving average is $33.59. Collegium Pharmaceutical has a 1-year low of $21.43 and a 1-year high of $50.79.

Analyst Upgrades and Downgrades

COLL has been the topic of a number of recent research reports. Truist Financial started coverage on shares of Collegium Pharmaceutical in a research note on Wednesday, September 9th. They set a "buy" rating and a $49.00 price target on the stock. Weiss Ratings lowered shares of Collegium Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, September 4th. Needham & Company LLC lowered their target price on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. Leerink Partners began coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 9th. They set an "outperform" rating and a $45.00 target price on the stock. Finally, Oppenheimer began coverage on Collegium Pharmaceutical in a research report on Wednesday, September 23rd. They set an "outperform" rating and a $50.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $48.71.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.